Effect of metformin on the expression of non-coding long-term RNA in diabetic patients.

Investigation of Metformin effect on the expression of H19, MEG3, MALAT1 and GAS5 long non-coding RNA levels in patients with type 2 diabetes: a clinical trial study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190303042903N1

Enrollment

Registered

2019-03-17

Start date

1398-01-20

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type II in people New case. Diabetes mellitus due to underlying condition

Interventions

Since the people who are studying the New Case do not need a control group. After entering the study, these individuals receive a daily dose of metformin at a dosage of 1000 or 500 mg per day (based o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Has a fasting blood glucose level of 126 mg / dl

Exclusion criteria

Exclusion criteria: consumer metformin or any other hypoglycemic drug and any other drug like statin, antihypertensive, anti-inflammatory drug, and an ACE inhibitor. A group of patients with cardiovascular disease and inflammatory diseases (such as lupus, rheumatoid arthritis, etc.) A group of patients with a variety of cancers A group of type 2 of diabetes Group of people with hyperlipidemia and hypertension

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Triglyceride. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Total cholesterol. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Cholesterol in low density lipoprotein. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Cholesterol in high density lipoprotein. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Long non-coding RNA H19. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With Real-Time device.;Long non-coding RNA MALAT1. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With Real-Time device.;Long non-coding RNA MEG3. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With Real-Time device.;Long non-coding RNA GAS5. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With Real-Time device.	—

Measure

Time frame

Fasting blood glucose. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Triglyceride. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Total cholesterol. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Cholesterol in low density lipoprotein. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Cholesterol in high density lipoprotein. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With an auto-analyzer device.;Long non-coding RNA H19. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With Real-Time device.;Long non-coding RNA MALAT1. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With Real-Time device.;Long non-coding RNA MEG3. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With Real-Time device.;Long non-coding RNA GAS5. Timepoint: At the beginning of the study (before the intervention) and two months after taking metformin. Method of measurement: With Real-Time device.

—

Secondary

Measure	Time frame
Long-term non-encoding RNA expression H19. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Laboratory analysis.;Long-term non-encoding RNA expression MALAT1. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Laboratory analysis.;Long-term non-encoding RNA expression MALAT1. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Laboratory analysis.;Long-term non-encoding RNA expression GAS5. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Laboratory analysis.;Glucose. Timepoint: Before intervention and 2 months after intervention. Method of measurement: mg/dl.;HbA1c. Timepoint: After intervention. Method of measurement: Percentage.;Triglycerides. Timepoint: Before and after intervention. Method of measurement: mg\dl.;Waist. Timepoint: Before and after intervention. Method of measurement: centimeter.;Hip circumference. Timepoint: Before and after intervention. Method of measurement: centimeter.;BMI. Timepoint: Before and after intervention. Method of measurement: Kg/m2.;Triglyceride. Timepoint: Before and after intervention. Method of measurement: mg/dl.;LDL. Timepoint: Before and after intervention. Method of measurement: mg/dl.;HDL. Timepoint: Before and after intervention. Method of measurement: mg/dl.;Cholesterol. Timepoint: Before and after intervention. Method of measurement: mg/dl.	—

Measure

Time frame

Long-term non-encoding RNA expression H19. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Laboratory analysis.;Long-term non-encoding RNA expression MALAT1. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Laboratory analysis.;Long-term non-encoding RNA expression MALAT1. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Laboratory analysis.;Long-term non-encoding RNA expression GAS5. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Laboratory analysis.;Glucose. Timepoint: Before intervention and 2 months after intervention. Method of measurement: mg/dl.;HbA1c. Timepoint: After intervention. Method of measurement: Percentage.;Triglycerides. Timepoint: Before and after intervention. Method of measurement: mg\dl.;Waist. Timepoint: Before and after intervention. Method of measurement: centimeter.;Hip circumference. Timepoint: Before and after intervention. Method of measurement: centimeter.;BMI. Timepoint: Before and after intervention. Method of measurement: Kg/m2.;Triglyceride. Timepoint: Before and after intervention. Method of measurement: mg/dl.;LDL. Timepoint: Before and after intervention. Method of measurement: mg/dl.;HDL. Timepoint: Before and after intervention. Method of measurement: mg/dl.;Cholesterol. Timepoint: Before and after intervention. Method of measurement: mg/dl.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli mirzaei

Yasouj University of Medical Sciences

mirzaee3a2003@yahoo.com+98 74 3333 7230

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026